Pfizer has agreed to acquire Global Blood Therapeutics (GBT) for $5.4 billion cash, in a deal that continues the pharma giant’s spate of acquisitions made possible by the billions of dollars ...

Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.

Pfizer will acquire Global Blood Therapeutics, maker of the drug Oxbryta for sickle-cell disease, in an all-cash deal valued at $5.4 billion, the companies confirmed on Monday.The announcement follows ...

A month has gone by since the last earnings report for Global Blood Therapeutics (GBT). Shares have added about 15.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT) and its oral therapy Oxbryta for sickle cell disease for around $5 billion, according to press reports.

Global Blood Therapeutics, Inc. (GBT) Q4 2020 Results Earnings Conference Call February 24, 2021 4:30 PM ETCompany ParticipantsSteven Immergut - Senior Vice ...